Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 4

1.

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.

Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP.

J Clin Oncol. 2012 Jul 20;30(21):2615-23. doi: 10.1200/JCO.2010.34.5579. Epub 2012 Jun 4.

PMID:
22665533
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.

Harding J, Burtness B.

Drugs Today (Barc). 2005 Feb;41(2):107-27. Review.

PMID:
15821783
[PubMed - indexed for MEDLINE]
3.

Characteristics of triple-negative breast cancer.

de Ruijter TC, Veeck J, de Hoon JP, van Engeland M, Tjan-Heijnen VC.

J Cancer Res Clin Oncol. 2011 Feb;137(2):183-92. doi: 10.1007/s00432-010-0957-x. Epub 2010 Nov 11. Review.

PMID:
21069385
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches.

Chen JQ, Russo J.

Biochim Biophys Acta. 2009 Dec;1796(2):162-75. doi: 10.1016/j.bbcan.2009.06.003. Epub 2009 Jun 13. Review.

PMID:
19527773
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk